Page last updated: 2024-08-25

efaroxan and Ophthalmoplegia, Progressive Supranuclear

efaroxan has been researched along with Ophthalmoplegia, Progressive Supranuclear in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brefel-Courbon, C; Ladure, P; Lees, A; Montastruc, JL; Peyro-Saint-Paul, H; Rascol, O; Senard, JM; Sieradzan, K; Thalamas, C	1

Trials

1 trial(s) available for efaroxan and Ophthalmoplegia, Progressive Supranuclear

Article	Year
Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:4 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Benzofurans; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Neurologic Examination; Prospective Studies; Supranuclear Palsy, Progressive; Treatment Outcome	1998

Article

Year

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.

Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:4

Topics: Adrenergic alpha-Antagonists; Adult; Aged; Benzofurans; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Neurologic Examination; Prospective Studies; Supranuclear Palsy, Progressive; Treatment Outcome

1998